Effect of Zhibitai capsule combined with atorvastatin calcium in the treatment of coronary heart disease

中国基层医药 Pub Date : 2020-03-01 DOI:10.3760/CMA.J.ISSN.1008-6706.2020.05.022

Chang-xian Wang

{"title":"Effect of Zhibitai capsule combined with atorvastatin calcium in the treatment of coronary heart disease","authors":"Chang-xian Wang","doi":"10.3760/CMA.J.ISSN.1008-6706.2020.05.022","DOIUrl":null,"url":null,"abstract":"目的 \n探讨脂必泰胶囊联合阿托伐他汀钙治疗冠心病的临床疗效。 \n \n \n方法 \n选取德惠市中医院2017年3月至2019年3月收治的冠心病患者89例为研究对象，采用随机数字表法分为观察组45例和对照组44例。两组患者均予以硝酸酯类、钙离子拮抗剂、血管紧张素转换酶抑制剂等常规对症治疗，对照组在此基础上采用阿托伐他汀钙片治疗，观察组采用脂必泰胶囊联合阿托伐他汀钙片治疗。比较两组患者的临床疗效，观察患者治疗前后血脂指标的变化。 \n \n \n结果 \n观察组总有效率为91.1%(41/45)，高于对照组的75.0%(33/44)，两组差异有统计学意义(χ2＝6.937，P<0.05)。治疗后，观察组血清总胆固醇(TC)为(1.69±0.31)mmol/L、甘油三酯(TG)为(3.54±0.41)mmol/L，对照组分别为(2.04±0.35)mmol/L、(4.11±0.49)mmol/L，两组均低于治疗前(对照组：t＝6.671、5.681，观察组：t＝12.495、10.456，均P<0.05)，观察组均低于对照组，差异均有统计学意义(t＝6.357、6.120，均P<0.05)。 \n \n \n结论 \n在常规治疗基础上，脂必泰胶囊联合阿托伐他汀钙片治疗冠心病，能提高临床疗效，有效调节血脂水平。","PeriodicalId":10226,"journal":{"name":"中国基层医药","volume":"27 6","pages":"608-610"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国基层医药","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1008-6706.2020.05.022","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

目的探讨脂必泰胶囊联合阿托伐他汀钙治疗冠心病的临床疗效。方法选取德惠市中医院2017年3月至2019年3月收治的冠心病患者89例为研究对象，采用随机数字表法分为观察组45例和对照组44例。两组患者均予以硝酸酯类、钙离子拮抗剂、血管紧张素转换酶抑制剂等常规对症治疗，对照组在此基础上采用阿托伐他汀钙片治疗，观察组采用脂必泰胶囊联合阿托伐他汀钙片治疗。比较两组患者的临床疗效，观察患者治疗前后血脂指标的变化。结果观察组总有效率为91.1%(41/45)，高于对照组的75.0%(33/44)，两组差异有统计学意义(χ2＝6.937，P<0.05)。治疗后，观察组血清总胆固醇(TC)为(1.69±0.31)mmol/L、甘油三酯(TG)为(3.54±0.41)mmol/L，对照组分别为(2.04±0.35)mmol/L、(4.11±0.49)mmol/L，两组均低于治疗前(对照组：t＝6.671、5.681，观察组：t＝12.495、10.456，均P<0.05)，观察组均低于对照组，差异均有统计学意义(t＝6.357、6.120，均P<0.05)。结论在常规治疗基础上，脂必泰胶囊联合阿托伐他汀钙片治疗冠心病，能提高临床疗效，有效调节血脂水平。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

脂必泰胶囊联合阿托伐他汀钙治疗冠心病疗效观察

Objective: To explore the clinical efficacy of Zhibitai capsules combined with atorvastatin calcium in the treatment of coronary heart disease. Method: 89 patients with coronary heart disease admitted to Dehui Traditional Chinese Medicine Hospital from March 2017 to March 2019 were selected as the research subjects. They were randomly divided into an observation group of 45 cases and a control group of 44 cases using a random number table method. Both groups of patients were treated with routine symptomatic therapies such as nitrates, calcium antagonists, and angiotensin converting enzyme inhibitors. The control group was treated with atorvastatin calcium tablets on this basis, while the observation group was treated with Zhibitai capsules combined with atorvastatin calcium tablets. Compare the clinical efficacy of two groups of patients and observe the changes in blood lipid indicators before and after treatment. The total effective rate of the observation group was 91.1% (41/45), which was higher than 75.0% (33/44) of the control group, and the difference between the two groups was statistically significant（ χ 2=6.937, P<0.05). After treatment, the total cholesterol (TC) in the observation group was (1.69 ± 0.31) mmol/L and triglycerides (TG) was (3.54 ± 0.41) mmol/L, respectively. The control group was (2.04 ± 0.35) mmol/L and (4.11 ± 0.49) mmol/L, respectively. Both groups were lower than before treatment (control group: t=6.671, 5.681, observation group: t=12.495, 10.456, all P<0.05), and the observation group was lower than the control group, with statistically significant differences (t=6.357, 6.120, all P<0.05). Conclusion: On the basis of routine treatment, the combination of Zhibitai capsules and atorvastatin calcium tablets can improve clinical efficacy and effectively regulate blood lipid levels in the treatment of coronary heart disease.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

中国基层医药

CiteScore

0.10

自引率

0.00%

发文量

32251

期刊介绍： Since its inception, the journal "Chinese Primary Medicine" has adhered to the development strategy of "based in China, serving the grassroots, and facing the world" as its publishing concept, reporting a large amount of the latest medical information at home and abroad, prospering the academic field of primary medicine, and is praised by readers as a medical encyclopedia that updates knowledge. It is a core journal in China's medical and health field, and its influence index (CI) ranks Q2 in China's academic journals in 2022. It was included in the American Chemical Abstracts in 2008, the World Health Organization Western Pacific Regional Medical Index (WPRIM) in 2009, and the Japan Science and Technology Agency Database (JST) and Scopus Database in 2018, and was included in the Wanfang Data-China Digital Journal Group and the China Academic Journal Comprehensive Evaluation Database.